Clinical Trials Logo

Pulmonary Arterial Hypertension clinical trials

View clinical trials related to Pulmonary Arterial Hypertension.

Filter by:

NCT ID: NCT01557660 Withdrawn - Clinical trials for Pulmonary Arterial Hypertension

Inhaled Treprostinil for PAH: Open-label Extension

INTREPID - OL
Start date: June 2012
Phase: Phase 3
Study type: Interventional

Open-label extension of RIN-PH-302.

NCT ID: NCT01557647 Withdrawn - Clinical trials for Pulmonary Arterial Hypertension

Safety and Efficacy of Inhaled Treprostinil in Patients With PAH

INTREPID
Start date: June 2012
Phase: Phase 3
Study type: Interventional

To evaluate the effect of inhaled treprostinil compared to placebo on exercise capacity and time to clinical worsening.

NCT ID: NCT01508780 Withdrawn - Clinical trials for Pulmonary Arterial Hypertension

Combined Use of Angiography, Optical Coherence Tomography and Intravascular Ultrasound in Evaluation of Pulmonary Vascular Structure and Function in Patients With Pulmonary Arterial Hypertension Treated With Oral Bosentan

Start date: May 2012
Phase: Phase 4
Study type: Interventional

It has been hypothesized that one of the benefits of bosentan relates to pulmonary vascular remodeling. The investigators believe that this study will help document the nature of beneficial changes that occur in patients with Pulmonary Arterial Hypertension (PAH) in response to bosentan therapy. In turn, demonstrating that changes in pulmonary vascular structure and function accompany clinical improvement.

NCT ID: NCT01458236 Withdrawn - Clinical trials for Pulmonary Arterial Hypertension

A Multinational, Multicenter, Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonary Arterial Hypertension Currently Receiving Treatment With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor

Start date: November 2011
Phase: Phase 3
Study type: Interventional

A multinational, multicenter, double-blind, randomized, placebo-controlled, Phase III study to assess the efficacy and safety of BPS 314d-MR in subjects with pulmonary arterial hypertension currently receiving treatment with an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 Inhibitor (PDE-5 inhibitor). Approximately 100 centers will be participating in the study. Approximately 630 eligible subjects will be randomized 1:1 into two groups, BPS-314d-MR (active) or placebo study drug.

NCT ID: NCT01352026 Withdrawn - Clinical trials for Pulmonary Arterial Hypertension

Evaluation of Metformin Activity in Addition to Conventional Treatment of Grade II or III Pulmonary Arterial Hypertension (PAH)

MetHTAP
Start date: May 2011
Phase: Phase 2
Study type: Interventional

Treatment of PAH includes exercise limitation, non specific agents (anticoagulants, diuretics and supplemental oxygen), pulmonary specific vasodilators and antiproliferative agents. Recent data obtained by our group, within rat PAH models, showed that the antihyperglycemic drug metformin, used in France since 1959 in diabetic type II patients, significantly acts at the pulmonary arteries level. According to these results, and knowing that metformin is a widely used drug, with a favorable safety profile, the investigators decided to set up a pilot study, in order to evaluate the activity of metformin in PAH treatment. In parallel, the investigators will focus on metformin mechanism of action.

NCT ID: NCT01251848 Withdrawn - Clinical trials for Pulmonary Arterial Hypertension

Drug Interaction Between Ritonavir And Sitaxsentan

Start date: January 2011
Phase: Phase 1
Study type: Interventional

The study is to assess if sitaxsentan and ritonavir will affect the blood levels of each other when coadministered.

NCT ID: NCT01251835 Withdrawn - Clinical trials for Pulmonary Arterial Hypertension

Effect Of Rifampin On Pharmacokinetics Of Sitaxsentan

Start date: December 2010
Phase: Phase 1
Study type: Interventional

This study will assess how rifampin will affect the blood levels of sitaxsentan. Safety of sitaxsentan given alone and with rifampin will also be assessed.

NCT ID: NCT00722254 Withdrawn - Clinical trials for Pulmonary Arterial Hypertension

Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder

Start date: June 2006
Phase: N/A
Study type: Observational

To determine the prevalence of myelofibrosis in patients with primary pulmonary hypertension, and to discover if the fibrosis in these patients is primary (AMM) or secondary.

NCT ID: NCT00625469 Withdrawn - Clinical trials for Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan

Start date: October 2007
Phase: Phase 4
Study type: Interventional

Pulmonary Arterial Hypertension (PAH) in the setting of Idiopathic Pulmonary Fibrosis(IPF)is a risk factor for morbidity and mortality in the peri-lung transplant(LT) setting. Currently there is no significant data to support the use of pulmonary vasodilators for PAH in the setting of interstitial lung disease such as IPF. The majority of IPF patients have PAH either at rest or during exercise. The study hypothesis is that bosentan may improve morbidity and mortality in the peri-LT setting in both IPF cohorts with either resting or exercise PAH.

NCT ID: NCT00625079 Withdrawn - Clinical trials for Pulmonary Hypertension

Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil

Start date: February 2007
Phase: Phase 4
Study type: Interventional

Pulmonary Arterial Hypertension (PAH) in the setting of Idiopathic Pulmonary Fibrosis(IPF)is a risk factor for morbidity and mortality in the peri-lung transplant(LT) setting. Currently there is no significant data to support the use of pulmonary vasodilators for PAH in the setting of interstitial lung disease such as IPF. The majority of IPF patients have PAH either at rest or during exercise. The study hypothesis is that sildenafil may improve morbidity and mortality in the peri-LT setting in both IPF cohorts with either resting or exercise PAH.